Mirum Pharmaceuticals logo

Mirum Pharmaceuticals

MIRM | NASDAQ
Chart Builder DCF Calculator
$91.58
-$2.41 (-2.56%)
At close: Nov 16, 2026, 4:00 PM ET
$91.58
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-2.56%

Rating

Updated: Nov 16, 2026
39
Fundamentals Weak
Market Sentiment Bullish
Moat Narrow
Sector Rank #555/1021 (Top 54%)

Key Statistics

Market Data

Market Cap $5.98B
1D Range
91.04 94.31
52W Range
64.10 128.57

Valuation (TTM)

PE -5.92
PB -110.33
EV/EBITDA -7.50

Valuation (NTM)

Forward PE 876.87
Forward PEG -0.00
Price Target $146.00
Loading financial charts...

Profile

Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMAR...

Sector Healthcare
Industry Biotechnology
Employees 433
IPO Date Jul 18, 2019
Fiscal Year January - December

Latest News

MIRM's Brelovitug Scores Second Phase III Win, Nears BLA Filing in HDV

5 days ago · zacks.com

MIRM's Brelovitug Scores Second Phase III Win, Nears BLA Filing in HDV
Mirum's liver infection drug lowers virus levels in second late-stage study

6 days ago · reuters.com

Mirum's liver infection drug lowers virus levels in second late-stage study
Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD

6 days ago · businesswire.com

Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2026 Earnings Call Transcript

13 days ago · seekingalpha.com

Mirum Pharmaceuticals, Inc. (MIRM) Q3 2026 Earnings Call Transcript
Mirum Pharmaceuticals Q3 Earnings Call Highlights

13 days ago · marketbeat.com

Mirum Pharmaceuticals Q3 Earnings Call Highlights
Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q3 Earnings

13 days ago · zacks.com

Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q3 Earnings
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates

13 days ago · zacks.com

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver Meeting® 2026

15 days ago · businesswire.com

Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver Meeting® 2026
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

21 days ago · zacks.com

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases

1 month ago · zacks.com

Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases

Earnings

Latest Earnings
Nov 3, 2026
EPS
-$0.87
Miss -78.71%
REV
$185.72M
Beat +4.29%
Next Earnings
Feb 24, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
12
Consensus
Buy
Price Target
$146.00
Upside
+59.42%
Buy (12)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.